Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.

@article{Beksac2011AdditionOT,
  title={Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.},
  author={Meral Beksac and Rauf Haznedar and Tulin Firatli-Tuglular and Hakan Ozdoğu and Ismet Aydoğdu and Nahide Konuk and Gulsan A Sucak and Işık Kaygusuz and Sema Sadin Karakuş and E. E. Kaya and Rıdvan Ali and Zafer Gulbaş and Gulsum Ozet and Hakan Goker and Levent Undar},
  journal={European journal of haematology},
  year={2011},
  volume={86 1},
  pages={
          16-22
        }
}
The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules. This prospective trial differs from previous melphalan-prednisone (MP) vs. MPT trials by treatment dosing, duration, routine anticoagulation, and permission for a crossover. Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were… CONTINUE READING
Highly Cited
This paper has 84 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Bortezomib for previously untreated multiple myeloma.

Expert opinion on pharmacotherapy • 2011
View 11 Excerpts
Highly Influenced

Recognition of early mortality in multiple myeloma by a prediction matrix

American journal of hematology • 2017
View 8 Excerpts
Method Support
Highly Influenced

85 Citations

01020'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 85 citations based on the available data.

See our FAQ for additional information.